196 related articles for article (PubMed ID: 29674164)
21. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
[TBL] [Abstract][Full Text] [Related]
22.
Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
[TBL] [Abstract][Full Text] [Related]
23. Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors.
Adams SE; Lee N; Lugovtsev VY; Kan A; Donnelly RP; Ilyushina NA
Antiviral Res; 2019 Sep; 169():104539. PubMed ID: 31228489
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.
Matos AR; Resende PC; Miranda MD; Garcia CC; Caetano BC; Lopes JCO; Debur MC; Cury ALF; Vianna LA; Lima MC; Schirmer M; Gubareva L; Hurt AC; Brown DW; Siqueira MM
Antiviral Res; 2018 Jun; 154():35-43. PubMed ID: 29601892
[TBL] [Abstract][Full Text] [Related]
25. Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.
Pizzorno A; Abed Y; Plante PL; Carbonneau J; Baz M; Hamelin MÈ; Corbeil J; Boivin G
Antimicrob Agents Chemother; 2014 Nov; 58(11):6398-405. PubMed ID: 25114143
[TBL] [Abstract][Full Text] [Related]
26. Predicting Permissive Mutations That Improve the Fitness of A(H1N1)pdm09 Viruses Bearing the H275Y Neuraminidase Substitution.
Farrukee R; Gunalan V; Maurer-Stroh S; Reading PC; Hurt AC
J Virol; 2022 Aug; 96(15):e0091822. PubMed ID: 35867563
[TBL] [Abstract][Full Text] [Related]
27. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.
Butler J; Hooper KA; Petrie S; Lee R; Maurer-Stroh S; Reh L; Guarnaccia T; Baas C; Xue L; Vitesnik S; Leang SK; McVernon J; Kelso A; Barr IG; McCaw JM; Bloom JD; Hurt AC
PLoS Pathog; 2014 Apr; 10(4):e1004065. PubMed ID: 24699865
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
29. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
Tamura D; Nguyen HT; Sleeman K; Levine M; Mishin VP; Yang H; Guo Z; Okomo-Adhiambo M; Xu X; Stevens J; Gubareva LV
Antimicrob Agents Chemother; 2013 Dec; 57(12):6141-6. PubMed ID: 24080660
[TBL] [Abstract][Full Text] [Related]
30. Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan.
Chong Y; Matsumoto S; Kang D; Ikematsu H
Influenza Other Respir Viruses; 2019 Mar; 13(2):115-122. PubMed ID: 30548432
[TBL] [Abstract][Full Text] [Related]
31. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670
[TBL] [Abstract][Full Text] [Related]
32. Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
Fujisaki S; Imai M; Takashita E; Taniwaki T; Xu H; Kishida N; Yokoyama M; Sato H; Tashiro M; Odagiri T
J Infect Chemother; 2013 Oct; 19(5):891-5. PubMed ID: 23529501
[TBL] [Abstract][Full Text] [Related]
33. Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.
Burnham AJ; Baranovich T; Marathe BM; Armstrong J; Webster RG; Govorkova EA
Antimicrob Agents Chemother; 2014 May; 58(5):2718-30. PubMed ID: 24566185
[TBL] [Abstract][Full Text] [Related]
34. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
McKimm-Breschkin JL
Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):25-36. PubMed ID: 23279894
[TBL] [Abstract][Full Text] [Related]
35. Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.
Song MS; Marathe BM; Kumar G; Wong SS; Rubrum A; Zanin M; Choi YK; Webster RG; Govorkova EA; Webby RJ
J Virol; 2015 Nov; 89(21):10891-900. PubMed ID: 26292325
[TBL] [Abstract][Full Text] [Related]
36. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
Huang W; Cheng Y; Li X; Tan M; Wei H; Zhao X; Xiao N; Dong J; Wang D
J Infect Chemother; 2018 Sep; 24(9):729-733. PubMed ID: 29866491
[TBL] [Abstract][Full Text] [Related]
37. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
Samson M; Abed Y; Desrochers FM; Hamilton S; Luttick A; Tucker SP; Pryor MJ; Boivin G
Antimicrob Agents Chemother; 2014 Sep; 58(9):5220-8. PubMed ID: 24957832
[TBL] [Abstract][Full Text] [Related]
38. Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
Mohr PG; Williams J; Tashiro M; Streltsov VA; McKimm-Breschkin JL
Antiviral Res; 2020 Oct; 182():104895. PubMed ID: 32750469
[TBL] [Abstract][Full Text] [Related]
39. Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains.
Abed Y; Pizzorno A; Bouhy X; Boivin G
Antiviral Res; 2015 Feb; 114():57-61. PubMed ID: 25512229
[TBL] [Abstract][Full Text] [Related]
40. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
Perez-Sautu U; Pozo F; Cuesta I; Monzon S; Calderon A; Gonzalez M; Molinero M; Lopez-Miragaya I; Rey S; Cañizares A; Rodriguez G; Gonzalez-Velasco C; Lackenby A; Casas I
Euro Surveill; 2014 Jul; 19(27):14-20. PubMed ID: 25033052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
